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A Mutation in the Golgi Qb-SNARE Gene
GOSR2 Causes Progressive Myoclonus
Epilepsy with Early Ataxia
Mark A. Corbett,1,17 Michael Schwake,2,17 Melanie Bahlo,3,4 Leanne M. Dibbens,1,5 Meng Lin,2
Luke C. Gandolfo,3 Danya F. Vears,6 John D. O’Sullivan,7 Thomas Robertson,8 Marta A. Bayly,1
Alison E. Gardner,9 Annemarie M. Vlaar,10 G. Christoph Korenke,11 Bastiaan R. Bloem,12
Irenaeus F. de Coo,13 Judith M.A. Verhagen,14 Anna-Elina Lehesjoki,15 Jozef Gecz,1,5,9,16,*
and Samuel F. Berkovic6,*
The progressive myoclonus epilepsies (PMEs) are a group of predominantly recessive disorders that present with action myoclonus,
tonic-clonic seizures, and progressive neurological decline. Many PMEs have similar clinical presentations yet are genetically heteroge-
neous, making accurate diagnosis difficult. A locus for PME was mapped in a consanguineous family with a single affected individual to
chromosome 17q21. An identical-by-descent, homozygousmutation inGOSR2 (c.430G>T, p.Gly144Trp), a Golgi vesicle transport gene,
was identified in this patient and in four apparently unrelated individuals. A comparison of the phenotypes in these patients defined
a clinically distinct PME syndrome characterized by early-onset ataxia, action myoclonus by age 6, scoliosis, and mildly elevated
serum creatine kinase. This p.Gly144Trp mutation is equivalent to a loss of function and results in failure of GOSR2 protein to localize
to the cis-Golgi.Clinically, the progressive myoclonus epilepsies (PMEs)
can be usefully divided into two groups: those with an
associated prominent dementia (e.g., Lafora disease [MIM
254780] and neuronal ceroid lipofuscinoses1) and those
in which cognition is essentially preserved.2,3 The paradig-
matic form of the latter group is Unverricht-Lundborg
disease (ULD;MIM: 254800), which is caused bymutations
in CSTB (MIM 601145).4 However, there remains an
important group of cases that have a presentation resem-
bling ULD but are not explained by mutations in CSTB
or other known causes (e.g., mitochondrial disease). Muta-
tions in SCARB2 (MIM 602257) and PRICKLE1 (MIM
608500) have been described recently in such families,
but most cases remain unsolved.5–7 We studied one such
case in which the clinical onset was marked by ataxia
followed by a classic PME presentation without dementia.
The proband (case 1, II-1, Australian pedigree, Figure 1B)
was Australian, born to second-cousin parents of British
origin. When she was 2 years old, she was observed to
have difficulty walking. The patient was found to be are-
flexic, but development was otherwise normal. At age 7,
she had a tremor, and subsequently it became clear that
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The Amepresent. At age 13, she began having drop attacks as well
as major convulsive seizures. She required a wheelchair
from age 14 on because of falling attacks and was unable
to walk unaided from age 16 on. She had a severe scoliosis
requiring surgical correction. By age 22 she was bedfast,
and she died at age 32 because of complications from
uncontrolled myoclonus. Her intellect was preserved until
the last few years of her life, when there was mild cognitive
impairment. The EEG showed active generalized spike and
wave discharges, which worsened with intermittent photic
stimulation. Her MRI and nerve conduction studies were
normal.A complete autopsywasperformed.The immediate
cause of death was determined to be aspiration broncho-
pneumonia. The brain showed mild cerebral atrophy and
a relatively reduced whole-brain weight of 1129 g, as
opposed to a cerebellumweight of 138 g.No gross structural
abnormalitieswere identified at brain dissection.Histologic
examination revealed subtle, Alzheimer type II gliosis in the
basal ganglia region, consistent with metabolic derange-
ment related to her agonal state. There was minor loss of
Purkinje cell and gliosis in the cerebellar vermis but no
other focal neuronal degeneration. No abnormal storage
material or Lafora bodies were found with examination by2Department of Biochemistry, Universita¨t Kiel, Kiel D-24098, Germany;
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Figure 1. Identification of GOSR2 Mutation
(A) Graph showing the computed LOD scores for chromosome 17. A single peak, of width 9 cM, with the maximum possible LOD score
of 1.93 (indicated by the red highlighting) suggests linkage to a 9.5 Mbp region on chromosome 17 (indicated by the red box on the
ideogram). The tile path of regions targeted on the array is indicated by the black shaded regions below the ideogram of chromosome
17. Sequence coverage, calculated as the number of reads per bp of the linkage interval, is indicated in red in the lower graph.
(B) Pedigrees of five families with affected females and males (indicated by black circles and squares, respectively). Alleles carried by each
individual are indicated; only affected individuals are homozygous for the GOSR2 c.430G>T mutation. Below the pedigrees are sizes of
products in bp generated by amplification by PCR of microsatellite markers flankingGOSR2 (indicated on the left) for each affected indi-
vidual. The red lettering indicates haplotypes observed in more than one individual.
(C) The three isoforms of GOSR2 (A, B, and C) are shown by exon structure in the context of genomic DNA (upper half) and the domain
structure of the corresponding translated protein products (lower half). Exons are indicated by boxes, and introns are shown as thin
lines. Black shading of the exons indicates the open reading frame, whereas gray shading shows untranslated regions. Isoforms A, B,
and C correspond to NM_004287.3, NM_054022, and NM_001014511.1, respectively. On the protein structures, the coiled-coil (CC),
Q-SNARE (as indicated), and transmembrane (TM) domains are shown.
(D) A CLUSTALWalignment of orthologs of GOSR2 frommultiple species. The orthologs were identified by using the homologene data-
base, tblastn search of the NCBI nonredundant sequence database, and the SNARE database24. Species names and amino acid residue
ranges are labeled on the left of the alignment. Identical residues are indicated by the gray background. Gly144 and the corresponding
residue in other species are indicated by the black arrowhead; the glutamine residue from which the Q-SNARE gets its name is indicated
by the white arrowhead. We performed alignments by using the EBI CLUSTALW server.25periodic acid-Schiff histochemical stain or by electron
microscopy of the cerebrum and cerebellum. The Golgi
apparatus identified in lymphoid cells (Figure S1, available
online) and anterior pituitary cells appeared normal.
We genotyped the subject, her unaffected brother, and
her parents by using Affymetrix 250K Nsp SNP chips for
the purpose of linkage mapping. Homozygosity mapping
was performed as described previously8 and identified
a single region between rs3914090 and rs2240222 on chro-
mosome 17 (chr17:36,483,334-46,021,780 bp; UCSC hg18
Genome Build) that achieved suggestive linkage attaining
the maximum possible LOD score of 1.93 (Figure 1A).658 The American Journal of Human Genetics 88, 657–663, May 13,We designed an on-array (Roche/Nimblegen) sequence-
enrichment strategy for the chromosome 17 interval,
totaling 3.29 Mbp of unique sequence. Probes on the array
were based on the genomic coordinates from UCSC hg18
March 2006 genome build for Refseq genes, all human-ex-
pressed sequence tags (ESTs), and putative promoters,
defined as 2 kb upstream of the first exon of a Refseq.
Enriched DNA was sequenced on the Illumina GAIIx
platform. We assembled reads to the hg18 build of the
human genome by using Burrows-Wheeler Alignment
tool and the Galaxy genome-analysis tool9,10 with default
parameters, except for -d 5, -l 35, and -k 3.11 Eighty-eight2011
Figure 2. GOSR2 Mutation, p.Gly144Trp, Functional Analysis
(A–D) Example images taken by indirect immunofluorescent
confocal microscopy of cultured primary human fibroblast cell
lines derived from an unaffected female control (A and C) and
case 1 (B and D). Cells were grown on glass coverslips, fixed with
4%paraformaldehyde, and then permeabilized with 0.2% saponin
in phosphate buffered saline (PBS). The cells were then stained
with an antibody specific to GOSR2 (mouse pAB, Abnova, Taipei
City, Taiwan) (A–D; red channel) and costained with either the
Golgi specific marker GOLGA2 (rabbit pAB, Abnova) (A and B)
or the endoplasmic reticulum marker PDI (rabbit pAB, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) (C and D; green
channel). Cells were embedded in Mowiol containing 4’, 6-diami-
dino-2-phenylindole (DAPI; blue channel) to stain nuclei and
Dabco (Sigma Aldrich, Steinheim, Germany) as an antifading
agent. Note that only the control cell line has evidence of costain-
ing of GOLGA2 with GOSR2 (A; indicated by the yellow color). (E)
Bos1 p.Gly176Trp cannot substitute bos1. Yeast strain BY4742
strain26 was transformed with pRS316-bos1 and the resulting
strain transformed with bos1 deletion cassettes constructed with
PCR.27 5-fluoroorotic acid (5-FOA) is converted by Ura3 (present
in pRS316-bos1) to 5-fluorouracil, which is toxic for the cell. We
used negative selection with 5-FOA to confirm the bos1 deletion
(Dbos1) strain. The pRS315-bos1 and pRS315-bos1-Gly176 vectors
allow expression of the wild-type andmutant bos1 under negative
selection conditions. Serial dilutions (1:10) of the indicated strains
were spotted on SC-Leu/Ura and 5-FOA plates and incubated at
30C for 48 hr. Only cells that lack a functional bos1 gene after
negative selection for the pRS316-bos1 vector on the 5-FOA plates
failed to thrive. Results indicate that cells transformed with
pRS315-bos1-Gly176Trp are equivalent to the Dbos1 strain.percent of bases tiled on the array were covered with at
least ten 65 bp sequence reads (Figure 1A and Figure S2).
Sequence variants were reported with SAMTools12 and
categorized with SeattleSeq. We identified 2055 sequence
variants (Table S1) at a minimum of a 10-fold sequence
coverage, in which the discrepant base accounted for at
least 85% of the sequence reads (indicative of homozygous
variants). Filtering based on dbSNP131 retained 121
unique variants (Table S1), and only four of these located
to open reading frames (ORFs) or a splice site. Of the four
variants, one was synonymous, and three were predicted
to cause amino acid change: KRT16 (MIM 148067),
c.1223C>T, p.Thr408Met, (NM_005557.3); COASY (MIM
609855), c.1628G>A, p.Arg543His (NM_025233.5); and
GOSR2 (MIM: 604027), c.430G>T, p.Gly144Trp,
(NM_004287.3) (Table S2). Sequencing a cohort of 73 unre-
lated individuals with unresolved PME revealed that five
additional individuals from four families had the same
homozygous GOSR2 variant, c.430G>T, p.Gly144Trp,
that was identified in case 1, (Figure 1B). No consanguinity
was reported in their families. The c.430G>T GOSR2
variant was not observed in 584 chromosomes from
unaffected individuals or in dbSNP132. One of the four
additional families was of German ancestry and the three
others were of Dutch ancestry. Further analysis of one
affected individual from each family with both microsatel-
lite markers and Illumina 610 quad SNP chips revealed
a founder haplotype that was most likely of European
ancestry (Figure 1B and Table S3). All of the individuals
tested with the SNP chips shared the same minimal haplo-
type (104 SNPs, spanning 0.3 cM) (Table S3). The two other
missense variants identified in case 1 are located outside of
this minimal haplotype; therefore, we focused further
studies on the GOSR2 c.430G>T, p.Gly144Trp, mutation
as the most likely cause of PME in these families.
GOSR2 is a member of the Qb-SNARE family of vesicle
docking proteins.13,14 There are three known alternatively
spliced isoforms of GOSR2 (A, B, and C), (Figure 1C), and
allarepredicted tobeaffectedby thec.430G>T,p.Gly144Trp
mutation. The glycine 144 residue (G144) is within the
Qb-SNARE domain and shows remarkable conservation
from mammals through to yeast13 (Figure 1D). Moreover,
this position is occupied by either a glycine or a similarly
sized alanine residue within all human Qb-SNARE
proteins.14 Initially, we examined the possibility that the
p.Gly144Trp substitution might affect GOSR2 protein
stability; however, this was not altered (Figure S3). Interac-
tion of the mutant GOSR2 with ARF1 measured by the split
ubiquitin yeast two-hybrid method15 was also not affected
(Figure S4). Mutation of the equivalent glycine residue to
aspartate in similar Qb-SNAREproteins prevents interaction
between SNARE domains.13,16,17 We therefore investigated
the subcellular localization ofGOSR2 and a known cis-Golgi
marker GOLGA218 by indirect immunofluorescent staining
and confocal microscopy of a patient-derived, primary skin
fibroblast cell line. This showed that the GOSR2
p.Gly144Trpmutant protein fails to localize to the cis-GolgiThe Ame(Figures 2A–2D). The likely pathogenicity of the
p.Gly144Trp mutation was investigated by constructing
a yeast strain lacking the orthologous bos1 (Dbos1) (see
Tables S4 for plasmids Table S5 for yeast strains). The Dbos1
strain failed to thrive and could not be rescued by the intro-
duction of bos1 carrying the orthologous (p.Gly176Trp)
mutation (Figure2E).This suggests thatp.Gly144Trp is likely
to be equivalent to a loss of function mutation.
The age of the c.430G>T, p.Gly144Trp mutation in
GOSR2 was estimated with a statistical model thatrican Journal of Human Genetics 88, 657–663, May 13, 2011 659
Table 1. Comparison of Individuals with GOSR2 (c.430G>T) Mutation
Case Sex Origin
Known
Consan
guinity
Age
(Years)
First
Symptoms Other Seizuresa Motor Cognition
Skeletal
Abnormalities EEG CK (Normal < 170)
1 F Australian Yes 32b ataxia, age 2; tremor,
age 7; absences,
age 7–8; obvious
myoclonus, age 8
drop attacks,
age 13; convulsive
seizures, age 13
areflexia, age 2;
wheelchair, age 14;
bedfast age, 22
normal until ~age 25;
mmemory difficulties
later
scoliosis,
pes cavus
generalized spike-wave,
posterior emphasis
photosensitive
570–800
2 F German No 17 ataxia, age 1–2;
tremor, age 4;
myoclonus, age 6
drop attacks, age 14;
myoclonic status
areflexia, age 2;
wheelchair, age 15
normal scoliosis generalized spike-wave,
posterior emphasis
photosensitive
150–580
3 F Dutch No 32 ataxia, age 3;
myoclonus, age 6
convulsive seizures,
age 14
areflexia, age 3;
wheelchair, age 13
normal scoliosis,
syndactly
generalized spike-wave
photosensitive
141–267
4 F Dutch No 30 ataxia, age 2c;
fine motor problems,
age 5; worsening
ataxia, age 7;
absences, ~age 6;
myoclonus, age 10
tonic-clonic, age 12;
drop attacks, age 14
areflexia, age 7;
wheelchair, age 24
normal until ~ age 25;
memory difficulties
later
scoliosis,
syndactly
generalized spike-wave,
posterior emphasis
photosensitive
700–900
5a F Dutch No 24b ataxia, age 2-3;
myoclonus, age 6
tonic-clonic seizures,
age 21
areflexia, age 6;
wheelchair , age 14
normal scoliosis generalized discharges
photosensitive
300–668
5b M Dutch No 28 ataxia, age 2–3;
myoclonus, age 5–6
tonic-clonic seizures,
age 24; absences;
tonic seizures
areflexia, age 3;
wheelchair, age 13
normal scoliosis generalized discharges
photosensitive
174–213
a The distinction between true tonic-clonic seizures and myoclonic status could not be made in some cases.
b Deceased.
c Initially regarded as an acute ataxia, which improved.
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describes the decay of haplotype sharing of the ancestral
genomic segment due to recombination events over
successive generations.19 Common approaches to dating
mutations that rely onmutant allele or haplotype frequen-
cies20 could not be applied to infer the age of the mutation
because of the small sample size. The decay of haplotype
sharing model states that the remaining ancestral segment
length after t generations has a gamma(2,t) distribution
when the Haldane crossover model (no interference) is
assumed. The model assumes neutral evolution, but the
estimates can be shown to be unaffected by selection. We
assumed that there was no selection because the disease
is rare and recessive. A mutation age estimate was derived
by taking a sample of n ancestral segment lengths, li,
estimated from cases 1–4 and 5b and then deriving a bias
corrected maximum likelihood estimate (MLE) of the
t parameter in the model that is t ¼ (2n 1) / (P li). Ances-
tral segment lengths were measured in Morgans and
defined by regions where two or more affected individuals
share identical homozygous SNPs flanking the c.430G>T
mutation in GOSR2 (Table S3). A small tract containing
23 heterozygous SNPs covering approximately 500 kb
was observed in cases 3 and 4. We assumed that the ances-
tral segment extends beyond this point for another 136
markers where cases 1–4 share identical homozygous SNP
genotypes (Table S3). A copy number variant (CNV) anal-
ysis of this heterozygous tract with PennCNV21 did not
detect a CNV (specifically a duplication), suggesting that
the heterozygous tract in cases 3 and 4 might result from
a double-recombination event. To derive theMLE, we plau-
sibly assumed the ancestral segments in each affected indi-
vidual were approximately the same age. We also assumed
that the lengths were independent, which is equivalent to
assuming the segments descend independently in the
genealogy (a star-shaped genealogy). We obtained the exact
confidence interval (CI) by deriving the sampling distribu-
tion of a pivotal quantity involving the estimate and the
true mutation age by using known properties of the
gamma distribution. In this case, the reported CI is only
approximate because its derivation depends crucially on
the independence assumption, and cases 3 and 4 share
a comparatively recent ancestor based on their shared
heterozygous marker tract that invalidates the indepen-
dence assumption. We estimate the age of the mutation
in GOSR2 to be 181 generations with a 95% CI of (96,
343). Assuming a generation time of 20 years, this gives
an age estimate of approximately 3,600 years.
The clinical histories of all six cases with the c.430G>T
GOSR2 mutation (Table 1) showed remarkable concor-
dance; difficulty in walking was noticed in early childhood
and was followed by the onset of actionmyoclonus around
the age 6, sometimes associated with absence seizures.
Tonic-clonic seizures were infrequent, but by their mid-
teens five out of six subjects were wheelchair dependent
because of sudden epileptic falls. Cognition was generally
preserved, although there was some impairment in the
third decade. All six cases had scoliosis, and two hadThe Amesyndactyly. EEGs showed an active generalized spike and
wave and polyspike activity, often with a posterior
predominance and with prominent photosensitivity
(Figure S5). All cases had borderline or mildly elevated
serum creatine kinase (CK); however, muscle histology
and electromyography were normal, and the elevated CK
was thought not to be explicable by muscle contractions
due to seizures. MRI brain scans were normal except for
mild cerebellar atrophy in one.
PMEs pose a significant challenge in accurate diagnosis
because they are genetically heterogeneous and have rela-
tively similar clinical presentations. The identification of
mutations of GOSR2 has helped to define a distinct form
of PME that is distinguished by the early onset of ataxia
by around age 2 and action myoclonus that develops
around age 6. Unlike ULD, the course is relentlessly
progressive and motor disability requires a wheelchair by
the teens and further progression in the third decade. Scoli-
osis is not usually seen in PME; however, its presence in all
six cases suggests it is part of the core phenotype. Other
clinical clues could be syndactyly and a raised serum CK.
PMEs are remarkable for the relatively consistent clinical
pattern of myoclonus, convulsive seizures, ataxia and
generalized spike and wave discharges. Most of the gene
products mutated in PMEs are known to be involved
with posttranslational modification of proteins.3 GOSR2
is no exception; it has a role in protein transport from
the endoplasmic reticulum and into the Golgi appa-
ratus.22 Furthermore, blocking the activity of bos1 in yeast
leads to a specific defect in posttranslational modification
of glycophosphotidylinositol (GPI) anchored proteins.23
Such molecular convergence suggests that certain
neuronal groups might be particularly vulnerable to
impaired posttranslational processing resulting in the
characteristic phenotype of PME.Supplemental Data
Supplemental Data include five figures and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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